Financial Times perspective: The inside story of the Pfizer vaccine

US vaccine maker Pfizer, unlike AstraZeneca and J&J, made profit a priority in supplying Covid-19 vaccines into a market it now dominates.
Published on

South Africa features prominently in the FT's piece below on Pfizer, the US vaccine maker which deliberately and unashamedly set about extracting maximum profit from the Covid-19 pandemic. As the section on SA explains (the type is in bold), local politicians initially kicked back against "lawyered-up" negotiators from the Big Pharma multinational. But as deaths and public pressure rose, they submitted to Pfizer's onerous terms (including an unprecedented liability exclusion clause). That movie was re-run all around the world. As a result, only Pfizer shareholders now have any warm feelings towards the company. To paraphrase Oxfam's Winnie Byanyima, Pfizer could have saved the world, but chose to put profit ahead of that opportunity. While Pfizer's bank accounts are bulging, there's an obvious risk of its hardball approach coming back to bite one day. From an SA perspective, next time you hear ANC heavyweights railing against capitalism, it will be difficult to dismiss it as the raving of an economic illiterate. As you'll read, Pfizer's management and board decided early that the Covid-19 pandemic was the kind of profit-generating opportunity which only emerges once in a career. So, unlike the more altruistic approach of AstraZeneca and J&J, this American company is riding the money wave as hard as it possible can. – Alec Hogg

Use Spotify? Access BizNews podcasts here.

Use Apple Podcasts? Access BizNews podcasts here.

___STEADY_PAYWALL___

Loading content, please wait...

Related Stories

No stories found.
BizNews
www.biznews.com